Roivant's Mayukh Sukhatme plans $5M stock sale
Roivant Sciences Ltd. (ROIV) received a notice that Mayukh Sukhatme plans to sell common shares under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Roivant Sciences Ltd. (ROIV) received a notice that Mayukh Sukhatme plans to sell common shares under Rule 144. The planned sale covers 136,942 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,029,208.64 as of the notice.
These shares are to be issued via exercise of options under a registered plan on 08/18/2026, with sales on NASDAQ. Roivant had 722,323,000 shares outstanding of this class. Over the past three months, Sukhatme reported several prior sales of Roivant common shares.
Key Figures
Key Terms
Rule 144 regulatory
Exercise of Options Under a Registered Plan financial
aggregate market value financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.